Mepolizumab was first approved by the U.S. Food and Drug Administration (FDA) on November 4, 2015. [1]
What is Mepolizumab used for?
Mepolizumab is indicated for the treatment of severe eosinophilic asthma in patients aged 12 years and older. It is also approved for the treatment of eosinophilic granulomatosis with polyangiitis in patients aged 12 years and older, and for the maintenance treatment of patients with active eosinophilic esophagitis (EoE) aged 12 years and older. [1]
When did Mepolizumab become available in other regions?
In Europe, Mepolizumab received its initial marketing authorization on November 17, 2015. [2]
What is the mechanism of action for Mepolizumab?
Mepolizumab is a monoclonal antibody that targets interleukin-5 (IL-5). IL-5 is a key cytokine that plays a central role in the growth, activation, survival, and recruitment of eosinophils. By binding to IL-5, Mepolizumab inhibits its biological activity, thereby reducing the number of eosinophils. [3]
When does Mepolizumab's patent protection expire?
Information regarding specific patent expiry dates for Mepolizumab can be found on DrugPatentWatch.com. [4]